AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31558274
Drug: Single-implant participants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-implant participants
Trial: 31558274
Drug: 2-implant participants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-implant participants
Trial: 10783998
Drug: Non-sulphasalazine 5-ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-sulphasalazine 5-ASA drug
Trial: 8875814
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) 5‐mg, 10‐mg, 15‐mg, 20‐mg
Trial: 6337306
Drug: Propranolol 80
RxNorm normalized name: propranolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 80 mg daily postoperatively
Trial: 27649641
Drug: Gonadotropin‐releasing hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropin‐releasing hormone agonist (GnRHa) goserelin
Trial: 24091175
Drug: Prophylactic doses
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic doses of low molecular weight heparin
Trial: 16394886
Drug: Subcutaneous bolus
RxNorm normalized name: subcutaneous bolus insulin patch pump, 200 unit, disposable 2 unit MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous bolus injection of deferoxamine (DFO)
Trial: 16394886
Drug: Subcutaneous continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous continuous infusion of deferoxamine (DFO)
Trial: 16394886
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Subcutaneous bolus injection and Subcutaneous continuous infusion)
Trial: 11117271
Drug: Local allergoid
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local allergoid immunotherapy for 3 months before the pollen season
Trial: 9338948
Drug: Extra self‐administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra self‐administered fitness training
Trial: 3887393
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with anti-thymocyte globulin (ATG)
Trial: 3887393
Drug: Sequential combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential combination of ATG with Cys
Trial: 30821824
Drug: Gabapentin (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (1200 mg preoperatively, 600 mg 3 times a day postoperatively for 72 hours)
Trial: 30821824
Drug: Active placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active placebo (lorazepam 0.5 mg preoperatively, inactive placebo postoperatively for 72 hours)
Trial: 28159043
Drug: Prophylactic antibiotics
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotics (Group 1)
Trial: 28159043
Drug: No prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prophylactic antibiotics (Group 2)
Trial: 12635534
Drug: Azithromycin alone
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin alone (500 mg i.v. for 1-2 days, then 250 mg orally for 7 days)
Trial: 12635534
Drug: Azithromycin with
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin with metronidazole (500 mg i.v. for 1-2 days, then 250 mg orally for 7 days + 400 mg or 500 mg metronidazole i.v. then orally for 12-14 days)
Trial: 12635534
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (including azithromycin alone, azithromycin with metronidazole, and comparator regimens)
Trial: 10874261
Drug: Enalaprilat infusion
RxNorm normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalaprilat infusion (3-hour duration)
Trial: 8517425
Drug: Pravastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (40 mg) administered once daily at bedtime
Trial: 8517425
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered once daily at bedtime
Trial: 23653431
Drug: Vitamin D-
RxNorm normalized name: Vitamin D-3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D- and calcium-fortified yogurt (FY) providing 10 μg/d vitamin D₃ and 800 mg/d calcium
Trial: 23653431
Drug: Nonfortified control
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonfortified control yogurt (CY) providing 280 mg/d calcium
Trial: 10799795
Drug: Diclofenac epolamine
RxNorm normalized name: Diclofenac Epolamine
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac epolamine patch applied twice daily for 2 weeks
Trial: 10799795
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch applied twice daily for 2 weeks
Trial: 23224717
Drug: Selective reporting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective reporting of antibiotic susceptibility data (2 to 4 antibiotics only)
Trial: 23224717
Drug: Usual full-length
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual full-length reporting of antibiotic susceptibility data (25 antibiotics)
Trial: 23224717
Drug: Selective reporting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective reporting of antibiotic susceptibility data
Trial: 23224717
Drug: Usual full-length
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual full-length reporting of antibiotic susceptibility data
Trial: 25085407
Drug: Chlorhexidine solution
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 99.0 g in 1 L TOPICAL SOLUTION [CHLORHEXIDINE Solution]
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine solution
Trial: 11118018
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous infusion of insulin lispro (CSII)
Trial: 11118018
Drug: Ultralente human
RxNorm normalized name: INSULIN,ULTRALENTE,HUMAN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultralente human insulin
Trial: 11118018
Drug: Long-acting insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting insulin analog glargine
Trial: 9007918
Drug: Topical fluocinolone
RxNorm normalized name: fluocinolone Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fluocinolone acetonide 0.1%
Trial: 9007918
Drug: Topical retinoic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical retinoic acid 0.05%
Trial: 8117604
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (cisplatin 100 mg/m2 on day 1 and etoposide 120 mg/m2 on days 1, 2, 3 every 3 weeks for 3 courses followed by radiotherapy 56 Gy on pre-treatment tumor volume and 40 Gy on mediastinum and bilateral supraclavicular nodes)
Trial: 3086849
Drug: Patch A
RxNorm normalized name: Biopatch Antimicrobial Dressing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch A
Trial: 3086849
Drug: Patch B
RxNorm normalized name: Eye Patch Black
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch B
Trial: 3086849
Drug: Patch C
RxNorm normalized name: WellPatch CAPSAICIN 0.025 % Medicated Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch C
Trial: 3086849
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between patches A and B
Trial: 27102981
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol 800μg
Trial: 27102981
Drug: Buccal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buccal misoprostol 800μg
Trial: 27102981
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol 800μg
Trial: 25069975
Drug: mRDTs introduced
RxNorm normalized name: PERCUTANEOUS INTRODUCER SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRDTs introduced in drug shops
Trial: 20429831
Drug: EC-ASA 81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC-ASA 81 mg once daily alone
Trial: 20429831
Drug: EC-ASA 81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC-ASA 81 mg once daily with acetaminophen 1 g four times daily
Trial: 20429831
Drug: EC-ASA 81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC-ASA 81 mg once daily with NAPSO 220 mg three times daily
Trial: 15939585
Drug: Third-generation non-steroidal
RxNorm normalized name: Third-generation cephalosporins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third-generation non-steroidal aromatase inhibitors (NS-AIs) anastrozole and letrozole
Trial: 15939585
Drug: Steroidal aromatase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroidal aromatase inhibitor (S-AI) exemestane
Trial: 12442882
Drug: Donepezil 5
RxNorm normalized name: donepezil 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 5 mg/day for the first 28 days and 10 mg/day thereafter (n = 102)
Trial: 10442786
Drug: Various treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatments in psychiatry
Trial: 10442786
Drug: Proven treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proven treatments applied by psychiatrists
Trial: 1632690
Drug: Preoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative radiation therapy and surgery (subset of 56 patients with locally advanced lesions)
Trial: 30914312
Drug: 19-G EBUS
RxNorm normalized name: MENTHOL 19 g in 100 TOPICAL PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 19-G EBUS needle
Trial: 30914312
Drug: 22-G EBUS
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 22-G EBUS needle
Trial: 27837934
Drug: Selumetinib 75
RxNorm normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selumetinib 75 mg
Trial: 27837934
Drug: Selumetinib 150
RxNorm normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selumetinib 150 mg (predicted)
Trial: 24840317
Drug: INSULIN‐PH20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INSULIN‐PH20
Trial: 18320064
Drug: CPG-DDS +
RxNorm normalized name: DDS
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CPG-DDS + artesunate 1 mg/kg
Trial: 18320064
Drug: CPG-DDS +
RxNorm normalized name: DDS
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CPG-DDS + artesunate 2 mg/kg
Trial: 18320064
Drug: CPG-DDS +
RxNorm normalized name: DDS
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CPG-DDS + artesunate 4 mg/kg
Trial: 18320064
Drug: Treatment emergent
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment emergent adverse events
Trial: 10874989
Drug: Maternal prepartum
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal prepartum treatment with antibiotics and/or steroids
Trial: 8609325
Drug: Ibutilide (0.005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibutilide (0.005 to 0.025 mg/kg body weight)
Trial: 7295460
Drug: Phenobarbitone 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbitone 80 mg
Trial: 7295460
Drug: Phenobarbitone 140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbitone 140 mg
Trial: 7295460
Drug: Phenobarbitone 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbitone 240 mg
Trial: 7295460
Drug: Phenobarbitone (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbitone (all doses)
Trial: 24842062
Drug: Initial bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial bone preparation followed by a 2-week delay before implant placement
Trial: 21400763
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for cruciate ligament injury
Trial: 12487321
Drug: Camphor-Crataegus berry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camphor-Crataegus berry combination (CCC) - 5 drops
Trial: 12487321
Drug: Camphor-Crataegus berry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camphor-Crataegus berry combination (CCC) - 20 drops
Trial: 12487321
Drug: Camphor-Crataegus berry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camphor-Crataegus berry combination (CCC) - 80 drops
Trial: 12487321
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 drops of a 60% alcoholic solution)
Trial: 2658793
Drug: Single-beta-lactam combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-beta-lactam combination
Trial: 31895303
Drug: Kangaroo mother
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kangaroo mother care (n = 30), provided twice a day until discharge
Trial: 29050753
Drug: Spray Cryotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray Cryotherapy (SCT)
Trial: 26086183
Drug: NBP 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NBP 200 mg three times daily
Trial: 1637215
Drug: Glucose-insulin-potassium infusion
RxNorm normalized name: glucose / potassium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-insulin-potassium infusion (500 mL of 30% glucose containing 300 units of insulin and 5 g of potassium chloride at a rate of 1.66 mL.kg‐1.h‐1 for 1 hour before cardiopulmonary bypass)
Trial: 27233840
Drug: Nicotine Replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine Replacement Therapy (NRT) - 21 mg daily maximum for 10 weeks
Trial: 27233840
Drug: Nicotine Replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine Replacement Therapy Plus (NRT+) - 35 mg daily maximum patches and gum/inhaler for up to 22 weeks
Trial: 27233840
Drug: Varenicline (VR)
RxNorm normalized name: Prostin VR
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Varenicline (VR) - 1 mg twice daily for up to 24 weeks
Trial: 24590752
Drug: Prenatal lipid‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal lipid‐based nutrient supplements (LNS)
Trial: 21785956
Drug: Multidisciplinary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary treatment program including massage therapy, ischemic pressure, aerobic exercise, and thermal therapy for 8 weeks
Trial: 21785956
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group continued medical treatment and participated in four educational sessions
Trial: 22258622
Drug: Classification-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classification-based treatment
Trial: 17346248
Drug: Oxcarbazepine (OXCZ)
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine (OXCZ) 1200 mg daily for 17 days
Trial: 17346248
Drug: Carbamazepine (CBZ)
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine (CBZ) 800 mg daily for 17 days
Trial: 30997657
Drug: Cavit G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cavit G
Trial: 21389120
Drug: MHD intravenously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MHD intravenously (250 mg infused over 30 min)
Trial: 21389120
Drug: OXC orally
RxNorm normalized name: oxcarbazepine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OXC orally (one film-coated 300-mg tablet)
Trial: 11920979
Drug: Modified treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified treatment including mirror confrontation
Trial: 9865192
Drug: Combination CO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination CO2 and PDL laser treatment
Trial: 2136969
Drug: Anaritide (human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaritide (human atrial natriuretic peptide 102‐126) administered as 1‐hour infusions at a rate of 0.03 to 0.3 micrograms/kg/min
Trial: 402543
Drug: Actihaemyl (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actihaemyl (0.5 ml per kg body weight)
Trial: 402543
Drug: Fludilat (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludilat (200 mg)
Trial: 402543
Drug: Trental (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trental (200 mg)
Trial: 24102928
Drug: Gabapentin enacarbil
RxNorm normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin enacarbil (GEn) 3,600 mg/day
Trial: 24102928
Drug: Gabapentin enacarbil
RxNorm normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin enacarbil (GEn) 1,200 mg/day
Trial: 24102928
Drug: Gabapentin enacarbil
RxNorm normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin enacarbil (GEn) 2,400 mg/day
Trial: 21576533
Drug: 100 mcg/d
RxNorm normalized name: Natpara 100 MCG/Dose Cartridge, 14 Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mcg/d selenium supplementation
Trial: 21576533
Drug: 200 mcg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mcg/d selenium supplementation
Trial: 21576533
Drug: 300 mcg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mcg/d selenium supplementation
Trial: 21576533
Drug: Selenium supplementation
RxNorm normalized name: Selenium supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium supplementation (all doses)
Trial: 14966737
Drug: Melatonin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (10 mg/kg) administered for 72 hours, starting within 3 hours after surgery.
Trial: 9455079
Drug: Thiopental (TPS)
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopental (TPS) 4 mg.kg‐1
Trial: 3285835
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg torasemide
Trial: 3285837
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg torasemide
Trial: 3285834
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg furosemide
Trial: 3285834
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg furosemide
Trial: 25560051
Drug: Terbinafine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine (250 mg once daily)
Trial: 25560051
Drug: Itraconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (200 mg once daily)
Trial: 18520293
Drug: Sunitinib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib at 50 mg daily for 4 of 6 weeks
Trial: 18520293
Drug: Sunitinib at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib at 37.5 mg daily (continuous dosing schedule)
Trial: 15496230
Drug: Serum insulin-like
RxNorm normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum insulin-like growth factor-1 levels in systemic lupus erythematosus patients
Trial: 15496230
Drug: Serum growth
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum growth hormone levels in systemic lupus erythematosus patients
Trial: 31714895
Drug: L-Citrulline 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Citrulline 15 g/d for 2 weeks
Trial: 22492584
Drug: Isomaltulose (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isomaltulose (50 g/day for 12 weeks)
Trial: 22492584
Drug: Sucrose (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose (50 g/day for 12 weeks)
Trial: 16236879
Drug: Single 2.0-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 2.0-g dose of azithromycin microspheres
Trial: 16236879
Drug: Extended-release clarithromycin
RxNorm normalized name: clarithromycin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release clarithromycin (1.0 g/d for 7 days)
Trial: 8198976
Drug: levamisole 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levamisole 2.5 mg kg‐1 day‐1 given for 2 days every week for 18 months
Trial: 8198976
Drug: placebo therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo therapy in the same schedule
Trial: 27387759
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months of oral antibiotics
Trial: 27387759
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further antibiotic treatment (control)
Trial: 19196360
Drug: Amlodipine/valsartan 5/160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/valsartan 5/160 mg
Trial: 24976417
Drug: Purported weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purported weight loss supplement (placebo)
Trial: 22551105
Drug: Warfarin (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (target INR 2.0 to 3.5)